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Safety Assessment in Pregnancy, Part II”.In pregnancy, immunological and physiological changes may
increase a woman’s risk of infections and their sequelae. The imma-
ture immune system of the fetus and neonate pose an additional
risk of infection and associated complications for the developing
infant, including preterm birth [1,2]. In 2016, it was estimated that
neonatal death accounted for approximately 45 percent of mortal-
ity among children less than five years of age [3]. Immunization in
pregnancy has emerged as an important and successful public
health intervention globally to reduce mortality and morbidity
among pregnant women, their developing fetuses and neonates,
and infants [4]. It may become a key strategy to address neonatal
mortality in particular. This is particularly true in low and mid-
dle-income countries (LMIC) where the burden of vaccine-pre-
ventable diseases is the greatest and access to basic health
services is limited.
An important aim of vaccinating pregnant women is to increase
pathogen-specific antibodies in the mother to protect against some
of the leading causes of morbidity in pregnant women [5]. Also,
high and protective levels of immunoglobulin G may be transferred
across the placenta from the vaccinatedmother to the fetus [6]. This
may reduce risk of transmitting infections to the infant and may
also directly provide passive immunity early in life, which is a per-
iod of vulnerability for the infant [6]. The success of maternal teta-
nus vaccination demonstrates this principle and is part of routine
care in many countries: 41 out of 59 countries achieved Maternal
and Neonatal Tetanus (MNT) elimination as a result of the MNT
Elimination programme in conjunction with the World Health
Organization (WHO) and UNICEF [7]. Influenza and pertussis vacci-
nes are being increasingly recommended as an integral part of
immunization in pregnancy programs. These programs have
demonstrated the feasibility and effectiveness of immunization in
pregnancy programs in high, middle and low-income countries.
New vaccines are being developed to prevent infections in pregnant
women and infants, including against Group B streptococcus, respi-
ratory syncytial virus, and cytomegalovirus [4].
Immunization in pregnancy is currently an underutilized strat-
egy and public awareness and acceptance could be improved.
Despite evidence for their safety and effectiveness in both mothers
and their infants, vaccine uptake in pregnancy remains low for
influenza and moderate for pertussis vaccine. The uptake of the
influenza vaccine in pregnancy rarely exceeds 50 percent in devel-
oped countries, even in countries with national vaccination strate-
gies in place. For example, 50 percent of women in the US were
vaccinated against influenza just before or during pregnancy inthe 2015–16 influenza season [8]. Influenza and pertussis vaccine
uptake in pregnancy in England was around 42 percent and 60 per-
cent, respectively in 2015–2016. The UK has among the highest
coverage rates globally, indicating the scale of potential improve-
ment [9]. The coverage of seasonal influenza vaccination in the
2014–15 influenza season in pregnant women in five EU Member
States was between 0.3% and 56.1% (median 23.6%). No country
achieved the EU target of 75 percent coverage among the risk
groups) [10]. In LMIC, influenza vaccine coverage amongst preg-
nant women is negligible in 35 of the 64 tropical countries that
recommend seasonal influenza vaccination for pregnant women
[11].
Barriers to vaccination in pregnancy are complex and vary
depending on the country and population. The safety of vaccines
administered during pregnancy is a key consideration for pregnant
women, healthcare providers, vaccine manufacturers, investiga-
tors, regulators, ethics committees and communities [4]. There is
a need for a globally harmonised approach to actively monitor
the safety of vaccines used in immunization programs for pregnant
women [12].
Historically, there was little standardization of case definitions
for adverse events following immunization (AEFI) [13]. This
resulted in limited comparisons of safety data across vaccine trials
and studies in pre- and post-licensure settings. The Brighton Col-
laboration (BC) was formed in 2000 to help to overcome this short-
coming [14]. Today, BC case definitions are used and recommended
for use by normative bodies such as the World Health Organization
(WHO), the US FDA, the European Medicines Agency, the US Cen-
ters for Disease Control and Prevention (CDC), and the European
Centre for Disease Prevention and Control (ECDC) [15].
The GAIA (Global Alignment of Immunization Safety Assess-
ment in Pregnancy) project (http://gaia-consortium.net), coordi-
nated by the Brighton Collaboration Foundation (BCF) and funded
by the Bill and Melinda Gates Foundation, was initiated in 2015
for an initial period of two years (2015–2016). This was a response
to the World Health Organization’s call for a globally harmonised
approach to actively monitor the safety of vaccines and immuniza-
tion in pregnancy programs with a specific focus on LMIC needs
and requirements [12]. In the GAIA project, experts from 13 organ-
isations (BCF, US National Institute of Health, WHO, Global Health-
care Consulting, University of Washington, Baylor College of
Medicine, Monash Institute of Medical Research, St. George’s
University of London, Erasmus University Medical Center, Cincin-
nati Children’s Hospital, Public Health Agency Canada, Synapse
Research Management Partners and International Alliance for Bio-
logical Standardization) collaborated with over 200 volunteers
worldwide who participated in 25 specific working groups [16].
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was created, bringing together experts in vaccinology, maternal
health, and neonatology from academia, public health institutes,
regulatory agencies, investigators and vaccine manufacturers from
LMIC and high-income countries. GAIA outputs include a landscape
analysis of available standards and guidance documents, compris-
ing regulatory guidance pertinent to immunization in pregnancy
from the Food and Drug Administration (FDA), the European
Medicines Agency (EMA) and the International Conference on Har-
monisation [4].
Further, GAIA has developed two guideline documents for a
harmonised conduct of clinical trials of vaccines in pregnant
women [17,18]. This includes recommendations for harmonised
collection, analysis and presentation of safety data, provides guid-
ance on the prioritisation and classification of data to be collected,
as well as guidance on study design, applicable in various settings,
including LMICs. The WHO Global Advisory Committee on Vaccine
Safety (GACVS) provided a highly supportive assessment of the
GAIA guidelines for clinical trials and considered them to be timely
and useful [19]. These guidelines may also inform safety monitor-
ing of vaccines already recommended for pregnant women (teta-
nus, influenza and pertussis).
The GAIA partners developed the first set of over 21 standard-
ized case definitions of prioritized obstetric and neonatal outcomes
based on the standard Brighton Collaboration process [20]. The
first 10 definitions were published in a special issue of the journal
Vaccine in December 2016. They comprise five obstetric (hyperten-
sive disorders of pregnancy, maternal death, non-reassuring foetal
status, pathways to preterm birth and postpartum haemorrhage)
and five neonatal outcomes (congenital anomalies, neonatal death,
neonatal infections, preterm birth and stillbirth) [21]. These were
complemented with definitions and assessment algorithms of
enabling terms (e.g., gestational age).
Moreover, a searchable database of terms (glossary), concept
definitions and ontology of over 3000 terms related to key events
for monitoring immunization in pregnancy was developed
(https://evs.nci.nih.gov/ftp1/GAIA/About.html). A map of disease
codes across coding terminologies, including MedDRA and ICD,
was created to enable pooling of data from various sources. An
online tool for automated case classification (single case or batch
classification) of events according to the standardized case defini-
tions has also been developed [12].
An investigator workshop assessing the usefulness and
applicability of GAIA guidelines and case definitions in clinical
trials and observational studies in LMIC, and an international
consensus conference were held at the National Institute of Health
(NIH) [22].
In this special issue, the next set of 11 case definitions including
five obstetric outcomes (abortion, antenatal bleeding, gestational
diabetes, dysfunctional labour, foetal growth retardation) and six
neonatal outcomes (low birth weight, small for gestational age,
neonatal encephalopathy, respiratory distress, failure to thrive
and microcephaly) are published. In the light of the important pub-
lic health benefit of immunization in pregnancy in particularly
LMIC and the significant challenges of conducting research in low
resource settings especially with pregnant women, the paper by
Kochhar et al. highlights pertinent aspects of study design, regula-
tory and safety monitoring considerations in these settings.
The GAIA outputs are already being increasingly utilized in the
field of immunization in pregnancy and maternal and child health
by key stakeholders such as clinical trialists, investigators, regula-
tors, and industry. Useful next steps would be monitoring the
implementation of GAIA outputs and a structured assessment of
their current field use in addition to systematic evaluation of GAIA
output performance and the impact on data quality. This couldguide refinement of tools, and updates of guidelines and case def-
initions in cyclical revision periods. A second way to stimulate sci-
entific progress could be by developing additional guidelines and
tools requested by investigators and key stakeholders, and estab-
lishing a central resource that may provide investigators and stake-
holders with the standards and tools they need.
The GAIA guidelines, definitions and tools will be applicable in
immunization in pregnancy pre-and post-licensure safety and
pharmacovigilance surveillance systems and may help supporting
enhanced surveillance and collection of safety data that can be
consolidated and compared across sites, countries, and programs
worldwide. A standardized approach to safety data collection and
reporting is likely to improve the acceptability and implementa-
tion of immunizations in pregnancy and subsequently help reduce
illness and death among pregnant women and infants globally.
Disclaimer
The findings, opinions, assertions contained in this consensus doc-
ument are those of the individual authors. They do not necessarily
represent the official positions of each author’s organization.
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